Lexology January 21, 2026
The convergence of artificial intelligence (AI) and life sciences is no longer a distant promise. Companies operating in the sector are actively embracing the technology and are already achieving measurable results. In the following exclusive report from White & Case, in association with Mergermarket, this new reality is explored in depth. Drawing on a proprietary survey of senior executives spanning human pharma and biotech, healthcare provision, medical devices and animal health, the report provides a comprehensive overview of where the sector stands and where it may be heading.
Recent market data demonstrates the scale and urgency of this shift. AI in the pharma market alone is projected to reach US$25.7 billion by 2030, up from around US$4 billion today, according...
Today's Sponsors
Today's Sponsor